chemotherapy

A majority of Stage III/IV patients can benefit from adjuvant chemotherapy.

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial.

Metaanalysis of the association of breast cancer subtypes and complete pathologic response to neo adjuvant chemotherapy.

111: A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumours of the testis (NSGCTT).

Adjuvant chemotherapy in older and younger women with lymphnode positive breast cancer.

Despite receiving adjuvant chemotherapy, patients with stage IIIB and IIIC colon cancer have about a 40% risk of developing metastatic disease, meaning that the disease has spread from the colon to distant organs.

The study defined underuse as omissions of radiotherapy after breast-conserving surgery, adjuvant chemotherapy after resection of hormone receptor-negative tumors [greater than or equal to] 1 cm, or hormonal therapy for receptor-positive tumors [greater than or equal to] 1 cm.

The study defined underuse as omissions of radiotherapy after breast-conserving surgery, adjuvant chemotherapy after resection of hormone receptornegative tumors >[greater than or equal to] 1 cm, or hormonal therapy for receptor-positive tumors [greater than or equal to] 1 cm.

9,10) In a meta-analysis, the delay of adjuvant chemotherapy of more than 8 weeks for colon cancer was associated with an inferior outcome.

However, in one systematic meta-analysis study, adjuvant chemotherapy for localized resectable soft-tissue sarcoma exists marginal survival benefit [4], implying that chemotherapy may have a role in selected MPNST patients.

Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

Cisplatin-based adjuvant chemotherapy is recommended by the American Society of Clinical Oncology for adjuvant chemotherapy and adjuvant radiation therapy of stages II to IIIA NSCLC published on JCO in 2007.

Receipt of indicated adjuvant chemotherapy, radiation, and hormonal therapy significantly reduces disease recurrence and improves survival among women with early-stage breast cancer (Clarke et al.

Although adjuvant chemotherapy is recommended for stage III and high-risk stage II colon cancer, uncertainty remains around the benefits of such chemotherapy for patients with stage II and III rectal cancer [7].

The evolution of improved outcomes in treating microscopic metastatic breast cancer is also the story of developing adjuvant chemotherapy for postoperative breast disease, he says.